Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of BGB-11417
monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the
recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy
dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule
in the evaluated disease types.